Tissue factor pathway inhibitor in tetracycline-induced pleuritis in rabbits

Thrombosis and Haemostasis

Volumn 79, Issue 3, 1998, Pages 649-655

  Idell, Steven ^a   Pendurthi, Usha ^a   Pueblitz, Siegfried ^a   Koenig, Kathleen ^a   Williams, Todd ^a   Rao, L Vijay Mohan ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; FIBRIN; TETRACYCLINE; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; IMMUNOHISTOCHEMISTRY; LUNG FIBROBLAST; MESOTHELIUM CELL; NONHUMAN; PLASMA; PLEURA FLUID; PLEURISY; PRIORITY JOURNAL; RABBIT;

EID: 0031936533     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614961     Document Type: Article

References (26)

1. Bignon J, Gee JBL. Pleural fibrogenesis. In: The pleura in health and disease. Chretien J, Bignon J, Hirsch A (eds.). New York: Marcel Dekker, 1985; 417-43.
2. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
3. Broze GJ, Jr, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochem 1990; 29: 7539-45.
4. Semeraro N, Colucci M. Tissue factor in health and disease. Thromb Haemost 1997; 78: 759-64.
5. Idell S. Coagulation, fibrinolysis and fibrin deposition in lung injury and repair. In: Pulmonary Fibrosis. Phan SH, Thrall RS (eds.). Lung Biology in Health and Disease, C. Lenfant, exec. ed. New York: Marcel Dekker 1995; 80: 743-76.
6. Strange C, Baumann MH, Sahn S, Idell S. Effects of intrapleural heparin or urokinase on the extent of tetracycline-induced pleural disease. Am J Crit Care Med 1995; 151: 508-15.
7. Tillet WS, Sherry S, Read CT. Use of streptokinase-streptodornase in treatment of postpneumonic empyema. J Thorac Surg 1951; 21: 275-97.
8. The Collaborative Group Investigators of Intrapleural Fibrinolysis: Jerjes-Sanchez C, Ramirez-Rivera A, Elizalde JJ, Delgado R, Cicero R, Ibarra-Perez C, Arroliga AC, Padua A, Portales A, Villareal A, Perez-Romo A. Intrapleural fibrinolysis with streptokinase as an adjunctive treatment in hemothorax and empyema. Chest 1996; 109: 1514-9.
9. Werling RW, Zacharski LR, Kisiel W, Bajaj SP, Memoli VA, Rousseau SM. Distribution of tissue factor pathway inhibitor in normal and malignant human tissues. Thromb Haemost 1993; 69: 366-9.
10. Osterud B, Bajaj MS, Bajaj SP. Sites of tissue factor pathway inhibitor (TFPI) and tissue factor expression under physiologic and pathologic conditions. Thromb Haemost 1995; 73: 873-5.
11. Sabharwal AK, Bajaj SP, Ameri A, Tricomi SM, Hyers TM, Dahms TE, Taylor FB Jr, Bajaj MS. Tissue factor pathway inhibitor and Von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Resp Crit Care Med 1995; 151: 758-67.
12. Rao LVM, Hoang AD. Purification and characterization of rabbit tissue factor. Thromb Res 1989; 56: 109-18.
13. Rao LVM, Robinson T, Hoang AD. Factor VIIa/tissue factor-catalyzed activation of factors IX and X on a cell surface and in suspension: A kinetic study. Thromb Haemost 1992; 67: 654-9.
14. Warr T, Rao LVM, Rapaport SI. Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: Effect of anti-tissue factor antibodies and measurement or plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-9.
15. Sandset P, Warn-Cramer BJ, Rao LVM, Maki SL, Rapaport SI. Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci 1991; 88: 708-12.
16. Rapaport S, Toneff T, Rimon A, Warn-Cramer BJ. The effect of immunodepletion of antithrombin III on the response of rabbits to Russell's viper venom-induced activation of factor X. Arterioscler Thromb Vasc Biol 1997; 17: 409-16.
17. Idell S, Zwieb C, Boggaram J, Holiday D, Johnson AR, Raghu G. Mechanisms of fibrin formation and lysis by human lung fibroblasts: influence of TGF-β and TNF-α. Am J Physiol Lung Cell Mol Physiol 1992; 263: L487-94.
18. Idell S, Pueblitz S, Emri S, Gungen Y, Gray L, Kumar A, Holiday D, Koenig KB, Johnson AR. Regulation of fibrin deposition by malignant mesothelioma. Am J Pathol 1995; 147: 1318-29.
19. Glauser FL, Otis PT, Levine RI, Smith WR. In vitro pleural fluid clottability and fibrinogen content. Chest 1975; 68: 205-8.
20. Glauser FL, Otis PT, Levine RI, Smith WR. Coagulation factors and fibrinogen in pleural effusions. Respiration 1976; 33: 396-402.
21. Idell S, Girard W, Koenig K, McLarty J, Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. Am Rev Resp Dis 1991; 144: 187-94.
22. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP. Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 1992; 79: 3219-26.
23. Rana SV, Reimers HJ, Pathikonda MS, Bajaj SP. Expression of tissue factor and factor VIIa/tissue factor activity in endotoxin or phorbol stimulated U 937 monocyte-like cells. Blood 1988; 71: 259-62.
24. Bajaj MS, Ameri A, Kuppuswamy MN, Bajaj SP. Expression of tissue factor pathway inhibitor (TFPI) and GATA-2 transcription factor by activated human monocytes. Blood 1993; 82: 343a.
25. Craighead JE, Kane AB. The pathogenesis of malignant and nonmalignant serosal lesions in the body cavitites consequent to asbestos exposure. In: The Mesothelial Cell and Mesothelioma. Jaurand MC, Bignon J (eds.). Lung Biology in Health and Disease, Lenfant C (ed.), 1994; 78: 79-102.
26. Gerwin B. Mesothelial Carcinogenesis. In: The Mesothelial Cell and Mesothelioma. Jaurant MC, Bignon J (eds.). Lung Biology in Health and Disease, Lenfant C (ed.), 1994; 78: 223-43.